Vigonvita Sciences (Shanghai) Co., Ltd. is a China-based biotechnology company focused on developing AAV gene therapies for rare neurological and genetic diseases. The company is leveraging established AAV manufacturing capabilities and expertise in neurodevelopmental disorders to build a pipeline of transformative therapies for conditions including [CDKL5 deficiency disorder](/diseases/cdkl5-deficiency-disorder) and related disorders[vigonvita2024].
Overview
Vigonvita is positioned at the intersection of China's rapidly growing biopharmaceutical sector and the global rare disease gene therapy landscape. The company has developed integrated capabilities in:
AAV vector engineering and design
GMP manufacturing for gene therapy products
Regulatory strategy for rare neurological diseases
Clinical development for pediatric populations
The company's primary focus is on monogenic neurological diseases where AAV-mediated gene delivery can provide meaningful clinical benefit with a single treatment administration[vigonvita2023].
Pipeline
VGN-XXX (CDKL5 Deficiency Disorder)
CDKL5 deficiency disorder is a severe neurodevelopmental condition caused by loss-of-function mutations in the [CDKL5](/genes/cdkl5) gene, characterized by early-onset seizures, developmental delay, and motor dysfunction. Vigonvita is developing an AAV gene therapy to deliver a functional copy of [CDKL5](/genes/cdkl5) to affected neurons[cdkl5pipeline].
...
Vigonvita Sciences (Shanghai) Co., Ltd. is a China-based biotechnology company focused on developing AAV gene therapies for rare neurological and genetic diseases. The company is leveraging established AAV manufacturing capabilities and expertise in neurodevelopmental disorders to build a pipeline of transformative therapies for conditions including [CDKL5 deficiency disorder](/diseases/cdkl5-deficiency-disorder) and related disorders[vigonvita2024].
Overview
Vigonvita is positioned at the intersection of China's rapidly growing biopharmaceutical sector and the global rare disease gene therapy landscape. The company has developed integrated capabilities in:
AAV vector engineering and design
GMP manufacturing for gene therapy products
Regulatory strategy for rare neurological diseases
Clinical development for pediatric populations
The company's primary focus is on monogenic neurological diseases where AAV-mediated gene delivery can provide meaningful clinical benefit with a single treatment administration[vigonvita2023].
Pipeline
VGN-XXX (CDKL5 Deficiency Disorder)
CDKL5 deficiency disorder is a severe neurodevelopmental condition caused by loss-of-function mutations in the [CDKL5](/genes/cdkl5) gene, characterized by early-onset seizures, developmental delay, and motor dysfunction. Vigonvita is developing an AAV gene therapy to deliver a functional copy of [CDKL5](/genes/cdkl5) to affected neurons[cdkl5pipeline].
Program Status (March 2026):
IND-enabling studies underway
IND filing anticipated 2026
Preclinical data supporting CNS delivery and expression
Manufacturing scale-up for clinical supply
Mechanism:
AAV vector (serotype selection optimized for CNS tropism)
Delivers full-length human CDKL5 cDNA
Intrathecal or intracisternal administration
Single-dose treatment
Development Considerations:
CDKL5 gene size (~4.8kb) fits within standard AAV cargo capacity
Cell-type targeting to excitatory neurons and specific brain regions
Juvenile toxicology studies in relevant models
Formulation optimized for pediatric administration
Additional Pipeline Programs
Vigonvita has indicated additional programs in development:
A key differentiator for Vigonvita is its established AAV manufacturing infrastructure:
GMP production: Established facilities in Shanghai capable of producing clinical-grade AAV
Scalable platform: Suspension cell culture systems for large-scale production
Quality systems: GMP compliance with international standards (FDA, EMA compatibility)
Vertical integration: In-house manufacturing enables cost control and supply security
This manufacturing capability allows Vigonvita to progress programs through clinical development without requiring third-party manufacturing agreements, which have been a bottleneck for many gene therapy companies[vigonvita2025].
Competitive Position
Vigonvita competes in the CDKL5 gene therapy landscape with: